Keywords
Diagnosis
Treatment
Biomarker
Submitted : 2024-07-10
Accepted : 2024-07-25
Published : 2024-08-09
Abstract
This review article explores phosphatase and tensin homolog (PTEN)’s role in head and neck squamous cell carcinoma (HNSCC) through comprehensive expression and methylation examinations, genetic mutation investigation, and prognostic evaluation. Using the UALCAN informational collection, PTEN expression examination uncovered a critical over-expression in HNSCC cells isolated from normal control samples, proposing its role in HNSCC multiplication. Further, analysis of PTEN expression across various clinical limits has shown critical up-regulation in different cancer development stages, racial groups, gender, and age classes within the context of HNSCC patients, suggesting its major role in cancer duplication. PTEN expression was validated by utilizing the GEPIA2.0 online tool, which showed PTEN expression was particularly significantly expressed in HNSCC cancer improvement when it appeared differently from normal control samples. Accordingly, examining PTEN validation across different phases of cancer advancement showed dysregulation in each of the four phases with the most raised expression in stage I and the least expression in stage IV. Thus, this study investigated the promoter methylation level of PTEN, figuring out a basic relationship between HNSCC samples and normal control samples. Analyzing promoter methylation across various clinical limits uncovered massive variations, with specific methylation patterns seen across malignant growth stages, race groups, gender, and age groups. Overall survival and disease-free survival (OS and DFS) utilizing the KM plotter tool showed a critical relationship between PTEN expression levels in HNSCC patients, showing high PTEN expression exhibited good overall survival when showed up distinctively comparable to low PTEN expression levels. In addition, in disease-free survival (DFS) evaluation HNSCC patients showing low PTEN expression experienced great DFS relative to HNSCC patients with high PTEN expression. Moreover, to validate PTEN expression against survival, the study examined the HNSCC patients into low and high-expression groups of PTEN. In HNSCC, low PTEN expression was connected with great overall survival (OS) when it appeared contrastingly relative to the high PTEN expression. In like manner, the study found that low PTEN expression level was connected with great DFS in HNSCC when it appeared contrastingly related to the high PTEN expression group. Genetic mutation analysis via cBioPortal identifies a minimal proportion of PTEN mutations in HNSCC, predominantly in-frame mutation, missense mutation, splice mutation, truncating mutation, and structural variant, indicating their basal significance in PTEN dysregulation within HNSCC. Further investigation of PTEN molecular components and their exchange inside the HNSCC microenvironment might disclose novel roads for designated treatment and accurate medication approaches in battling this harmful disease.
References
Solomon B, Young RJ, Rischin D, 2018, Head and Neck Squamous Cell Carcinoma: Genomics and Emerging Biomarkers for Immunomodulatory Cancer Treatments. Semin Cancer Biol, 52(Pt 2): 228–240.
Vokes EE, Weichselbaum RR, Lippman SM, et al., 1993, Head and Neck Cancer. The New England Journal of Medicine, 328(3): 184–194.
Sung H, Ferlay J, Siegel RL, et al., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3): 209–249.
Siegel RL, Miller KD, Jemal A, 2020, Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1): 7–30.
Pfister DG, Spencer S, Brizel DM, et al., 2014, Head and Neck Cancers, Version 2. Clinical Practice Guidelines in Oncology. Journal of National Comprehensive Cancer Network, 12(10): 1454–1487.
Chai RC, Lambie D, Verma M, et al., 2015, Current Trends in the Etiology and Diagnosis of HPV-Related Head and Neck Cancers. Cancer Med, 4(4): 596–607.
Vogelstein B, Kinzler KW, 2004, Cancer Genes and the Pathways They Control. Nature Medicine, 10(8): 789–799.
The Cancer Genome Atlas Network, 2015, Comprehensive Genomic Characterization of Head and Neck Squamous Cell Carcinomas. Nature, 517(7536): 576–582.
Li J, Yen C, Liaw D, et al., 1997, PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer. Science, 275(5308): 1943–1947.
Steck PA, Pershouse MA, Jasser SA, et al., 1997, Identification of a Candidate Tumour Suppressor Gene, MMAC1, at Chromosome 10q23.3 That Is Mutated in Multiple Advanced Cancers. Nature Genetics, 15(4): 356–362.
Gao J, Aksoy BA, Dogrusoz U, et al., 2013, Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signaling, 6(269): 2004088.
Cerami E, Gao J, Dogrusoz U, et al., 2012, The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discovery, 2(5): 401–404.
Li DM, Sun H, 1997, TEP1, encoded by a Candidate Tumor Suppressor Locus, is a Novel Protein Tyrosine Phosphatase Regulated by Transforming Growth Factor Beta. Cancer Research, 57(11): 2124–2129.
Stambolic V, Suzuki A, de la Pompa JL, et al., 1998, Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN. Cell, 95(1): 29–39.
Leslie NR, Yang X, Downes CP, et al., 2007, PtdIns(3,4,5)P(3)-Dependent and -Independent Roles for PTEN in the Control of Cell Migration. Current Biology, 17(2): 115–125.
Raftopoulou M, Etienne-Manneville S, Self A, et al., 2004, Regulation of Cell Migration by the C2 Domain of the Tumor Suppressor PTEN. Science, 303(5661): 1179–1181.
Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, et al., 2008, The Protein Phosphatase Activity of PTEN Regulates SRC Family Kinases and Controls Glioma Migration. Cancer Res, 68(6): 1862-1871.
Song MS, Salmena L, Pandolfi PP, 2012, The Functions and Regulation of the PTEN Tumour Suppressor. Nature Reviews Molecular Cell Biology, 13(5): 283–296.
Mayo LD, Donner DB, 2002, The PTEN, Mdm2, p53 Tumor Suppressor-Oncoprotein Network. Trends Biochem Science, 27(9): 462–467.
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al., 2017, UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 19(8): 649–658.
Tang Z, Kang B, Li C, et al., 2019, GEPIA2: An Enhanced Web Server for Large-Scale Expression Profiling and Interactive Analysis. Nucleic Acids Research, 47(W1): W556–W560.
Maciejczyk A, Szelachowska J, Czapiga B, et al., 2013, Elevated BUBR1 Expression Is Associated with Poor Survival in Early Breast Cancer Patients: 15-Year Follow-Up Analysis. J Histochem Cytochem, 61(5): 330–339.
Bray F, Ferlay J, Soerjomataram I, et al., 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68(6): 394–424.
Canning M, Guo G, Yu M, et al., 2019, Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. Frontier in Cell and Developmental Biology, 2019(7): 52.
Chow LQM, 2020, Head and Neck Cancer. The New England Journal of Medicine, 382(1): 60–72.
Chen Y, Luo TQ, Xu SS, et al., 2021, An Immune-Related Seven-lncRNA Signature for Head and Neck Squamous Cell Carcinoma. Cancer Medicine, 10(7): 2268–85.
Yang C, Mei H, Peng L, et al., 2020, Prognostic Correlation of an Autophagy-Related Gene Signature in Patients with Head and Neck Squamous Cell Carcinoma. Computational and Mathematical Methods in Medicine, 28:7397132.
Wang Y, Wei Z, Pan K, et al., 2020, The Function and Mechanism of Ferroptosis in Cancer. Apoptosis, 25(11–12): 786–798.
Liang JY, Wang DS, Lin HC, et al., 2020, A Novel Ferroptosis-Related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma. International Journal of Biological Sciences, 16(13): 2430–2441.
Zhuo S, Chen Z, Yang Y, et al., 2020, Clinical and Biological Significances of a Ferroptosis-Related Gene Signature in Glioma. Frontier of Oncology, 10(590861).
Luo H, Ma C, 2021, A Novel Ferroptosis-Associated Gene Signature to Predict Prognosis in Patients with Uveal Melanoma. Diagnostics, 11(2).
Mou Y, Wu J, Zhang Y, et al., 2021, Low Expression of Ferritinophagy-Related NCOA4 Gene in Relation to Unfavorable Outcome and Defective Immune Cells Infiltration in Clear Cell Renal Carcinoma. BMC Cancer, 21(1): 020–07726.
Hémon A, Louandre C, Lailler C, et al., 2020, SLC7A11 as a Biomarker and Therapeutic Target in HPV-Positive Head and Neck Squamous Cell Carcinoma. Biochemical and Biophysical Research Communications, 533(4): 1083–1087.
Zhu T, Shi L, Yu C, et al., 2019, Ferroptosis Promotes Photodynamic Therapy: Supramolecular Photosensitizer-Inducer Nanodrug for Enhanced Cancer Treatment. Theranostics, 9(11): 3293–3307.
Manning BD, Cantley LC, 2007, AKT/PKB Signaling: Navigating Downstream. Cell, 129(7): 1261–1274.
Ciuffreda L, Di Sanza C, Incani UC, et al., 2010, The mTOR Pathway: A New Target in Cancer Therapy. Current Cancer Drug Targets, 10(5): 484–495.
Ma XM, Blenis J, 2009, Molecular Mechanisms of mTOR-Mediated Translational Control. Nature Reviews Molecular Cell Biology, 10(5): 307–318.
Dowling RJ, Topisirovic I, Alain T, et al., 2010, mTORC1-Mediated Cell Proliferation, but Not Cell Growth, Controlled by the 4E-BPs. Science, 328(5982): 1172–1176.
She QB, Halilovic E, Ye Q, et al., 2010, 4E-BP1 is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors. Cancer Cell, 18(1): 39–51.
Hollander MC, Blumenthal GM, Dennis PA, 2011, PTEN Loss in the Continuum of Common Cancers, Rare Syndromes and Mouse Models. Nature Reviews Cancer, 11(4): 289–301.
Mirmohammadsadegh A, Marini A, Nambiar S, et al., 2006, Epigenetic Silencing of the PTEN Gene in Melanoma. Cancer Research, 66(13): 6546–6552.
Aguirre AJ, Brennan C, Bailey G, et al., 2004, High-Resolution Characterization of the Pancreatic Adenocarcinoma Genome. Proceedings of the National Academy of Sciences of the United States of America, 101(24): 9067–9072.
Zhou XP, Loukola A, Salovaara R, et al., 2002, PTEN Mutational Spectra, Expression Levels, and Subcellular Localization in Microsatellite Stable and Unstable Colorectal Cancers. The American Journal of Pathology, 161(2): 439–447.
Frattini M, Signoroni S, Pilotti S, et al., 2005, Phosphatase Protein Homologue to Tensin Expression and Phosphatidylinositol-3 Phosphate Kinase Mutations in Colorectal Cancer. Cancer Research, 65(23): 11227.
Naguib A, Cooke JC, Happerfield L, et al., 2011, Alterations in PTEN and PIK3CA in Colorectal Cancers in the EPIC Norfolk Study: Associations with Clinicopathological and Dietary Factors. BMC Cancer, 11(123): 1471–2407.
Dearden S, Stevens J, Wu YL, et al., 2013, Mutation Incidence and Coincidence in Non-Small-Cell Lung Cancer: Meta-Analyses by Ethnicity and Histology (mutMap). Annals of Oncology, 24(9): 2371–2376.
Eng C, 2003, PTEN: One Gene, Many Syndromes. Human Mutation, 22(3): 183–198.
Mester JL, Moore RA, Eng C, 2013, PTEN Germline Mutations in Patients Initially Tested for Other Hereditary Cancer Syndromes: Would Use of Risk Assessment Tools Reduce Genetic Testing? Oncologist, 18(10): 1083–1090.
Marsh DJ, Coulon V, Lunetta KL, et al., 1998, Mutation Spectrum and Genotype-Phenotype Analyses in Cowden Disease and Bannayan-Zonana Syndrome, Two Hamartoma Syndromes with Germline PTEN Mutation. Human Molecular Genetics, 7(3): 507–515.
Zhang HY, Liang F, Jia ZL, et al., 2013, PTEN Mutation, Methylation and Expression in Breast Cancer Patients. Oncology Letters, 6(1): 161–168.